A Phase 2a Study of Weekly Doses of GCS-100 in Patients With Chronic Kidney Disease
- First Posted Date
- 2013-05-01
- Last Posted Date
- 2015-09-01
- Lead Sponsor
- La Jolla Pharmaceutical Company
- Target Recruit Count
- 120
- Registration Number
- NCT01843790
- Locations
- ๐บ๐ธ
Denver Nephrology, Denver, Colorado, United States
๐บ๐ธSouthwest Clinical Research Institute, LLC, Tempe, Arizona, United States
๐บ๐ธCalifornia Institute of Renal Research, La Mesa, California, United States
Safety Study of GCS-100 to Treat Chronic Kidney Disease
- First Posted Date
- 2012-10-30
- Last Posted Date
- 2013-06-20
- Lead Sponsor
- La Jolla Pharmaceutical Company
- Target Recruit Count
- 29
- Registration Number
- NCT01717248
- Locations
- ๐บ๐ธ
Denver Nephrologists, PC, Denver, Colorado, United States
๐บ๐ธRenal Associates PA / Research Division, San Antonio, Texas, United States
๐บ๐ธCalifornia Institue of Renal Research, La Mesa, California, United States
GCS-100LE in Combination With Etoposide and Dexamethasone in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2008-10-21
- Last Posted Date
- 2013-06-25
- Lead Sponsor
- La Jolla Pharmaceutical Company
- Registration Number
- NCT00776802
- Locations
- ๐บ๐ธ
UCLA Medical Center, Los Angeles, California, United States
Safety and Efficacy Study of GCS-100LE in the Treatment of Multiple Myeloma
- First Posted Date
- 2008-02-07
- Last Posted Date
- 2013-06-25
- Lead Sponsor
- La Jolla Pharmaceutical Company
- Target Recruit Count
- 9
- Registration Number
- NCT00609817
- Locations
- ๐บ๐ธ
Dana Farber Cancer Institute, Boston, Massachusetts, United States
๐บ๐ธFroedtert & Medical College Clinics, Medical College of Wisconsin, Milwaukee, Wisconsin, United States
๐บ๐ธUniversity of Florida, Gainesville, Florida, United States
Study of the Safety of GCS-100 in Subjects With Chronic Lymphocytic Leukemia
- First Posted Date
- 2007-08-10
- Last Posted Date
- 2013-06-17
- Lead Sponsor
- La Jolla Pharmaceutical Company
- Target Recruit Count
- 12
- Registration Number
- NCT00514696
- Locations
- ๐บ๐ธ
Dayton Oncology & Hematology, Kettering, Ohio, United States
๐บ๐ธRocky Mountain Cancer Centers, Denver, Colorado, United States
๐บ๐ธTyler Cancer Center, Tyler, Texas, United States
Study of LJP 394 (Abetimus Sodium) in Lupus Patients
- Conditions
- First Posted Date
- 2006-10-19
- Last Posted Date
- 2015-09-01
- Lead Sponsor
- La Jolla Pharmaceutical Company
- Registration Number
- NCT00390091
- Locations
- ๐บ๐ธ
Wallace Rheumatic Study Center, Los Angeles, California, United States
๐บ๐ธAltoona Center for Clinical Research, Duncansville, Pennsylvania, United States
Study of LJP 394 in Lupus Patients With History of Renal Disease
- First Posted Date
- 2004-08-17
- Last Posted Date
- 2009-04-01
- Lead Sponsor
- La Jolla Pharmaceutical Company
- Target Recruit Count
- 943
- Registration Number
- NCT00089804
- Locations
- ๐บ๐ธ
Ohio State University Medical Center, Columbus, Ohio, United States
๐บ๐ธMiami Children's Hospital, Miami, Florida, United States
๐บ๐ธCRIA Research, Fort Lauderdale, Florida, United States
Safety and Efficacy Study of LJP 394 (Abetimus Sodium) to Treat Lupus Kidney Disease
- First Posted Date
- 2002-05-03
- Last Posted Date
- 2006-09-25
- Lead Sponsor
- La Jolla Pharmaceutical Company
- Target Recruit Count
- 330
- Registration Number
- NCT00035308
- Locations
- ๐บ๐ธ
Emory University School of Medicine, Renal Division, Atlanta, Georgia, United States
๐บ๐ธRheumatology Associates, Chicago, Illinois, United States
๐บ๐ธUniversity of Chicago, Chicago, Illinois, United States